Higher serum uromodulin associated with lower all-cause mortality risk in patients with CKD
Click Here to Manage Email Alerts
Higher serum uromodulin was associated with a lower risk for all-cause mortality and kidney failure in white patients with chronic kidney disease, according to findings from a published study.
“Lower eGFRs and higher urinary albumin creatinine ratio (ACR) are strongly associated with all-cause and cardiovascular mortality, progression of chronic kidney disease (CKD) and kidney failure,” Dominik Steubl, MD, from the department of nephrology at Technische Universitat Munchen, and colleagues wrote. “We observationally tested whether higher serum uromodulin values are associated with lower risk for mortality, major adverse cardiovascular events and kidney failure in the German CKD cohort.”
In a prospective, observational, nationwide cohort study, 5,217 participants were enrolled between 2010 and 2012. Serum uromodulin measurements were available from 5,134 patients and served as the basis of this analysis with 2% of patients reported as lost to follow-up after 4 years.
Study results showed patients in lower serum uromodulin quartiles had lower eGFR and higher albuminuria. Patients is this quartile also displayed a higher prevalence of diabetes, hypertension, coronary artery disease and history of stroke at baseline. Patient follow-up showed 335 patient deaths, 417 patient developments of major adverse cardiovascular events and 229 patient incidences of kidney failure.
Further multivariable analysis showed the highest quartile for serum uromodulin was associated with lower hazards for mortality, major adverse cardiovascular event and kidney failure when compared to the lowest quartile for serum uromodulin.
“Serum uromodulin might be a promising complementary circulatory marker to assess the mortality and kidney risk, along with markers of glomerular function, in patients with CKD,” Steubl and colleagues wrote. – by Kate Burba
Disclosures: Steubl reports no financial disclosures. Please see the study for all other authors’ disclosures.
Collapse
Steubl D, et al. CJASM. 2020;doi:10.2215/CJN.11780919.
Read more about
Click Here to Manage Email Alerts